Johnathan Stanley
Redding, CA (USA)
Role(s):
Other
Amylex Pharma
Find More Startups
Startup
Location:
Redding
Industry:
Other
Year Founded:
2008
Number Employees:
1-10 people
Business Stage:
Growth (not profitable)
Entity Type:
"C" Corporation
Description:
New Biotic Inc (NBI) is on the verge of medical breakthrough and years ahead of its competition. We are pioneers in the microbiome space which studies many of the 6,000 strands of bacteria in the human gut to prevent, diagnose and treat disease. Research and development is focused on the root causes of central nervous system (CNS) disorders, rather than just symptom management.
The company has developed a potentially game changing treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. It has obtained exciting initial pivotal human data using a microbiome formulation that could be a disease modifying therapeutic for ALS. RaphaLX™ was granted Orphan Drug Designation (ODD) by FDA.
The company is also in discussion with the FDA about the possible use of its patent pending blood diagnostic biomarker for use in ALS as a companion diagnostic biomarker. Biomarkers for other neurological and psychiatric disorders, including Alzheimer’s, Parkinson’s, MS, schizophrenia, bipolar, etc. are currently being validated. The company holds two provisional patents in diagnostic biomarkers for CNS disorders and a few others in various stages of processing.
Having multiple products in its pipeline New Biotic welcome partners, collaborators and investors to accelerate their product rollout in first quarter 2019.